Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.35 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4748831 | 0.73 | — | — | |
| SCHEMBL13826336 | 0.69 | — | — | |
| SCHEMBL22168365 | 0.68 | DPP4 (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1691932 | 0.67 | GRIN2D (0.32) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5260452 | 0.67 | DPP4 (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL21363994 | 0.67 | DPP4 (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5258960 | 0.67 | DPP4 (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL22044790 | 0.67 | DPP4 (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL11771323 | 0.67 | — | — | |
| SCHEMBL5544076 | 0.66 | TSHR (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453017-B2 | Antiviral therapies with phospholipase D inhibitors | VANDERBILT UNIVERSITY (US) | 2016-09-27 | — | — | US | claimed |
| US-20110033422-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | SCHERING CORPORATION | 2011-02-10 | — | — | US | claimed |
| EP-2260839-A2 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | Merz Pharma GmbH & Co. KGaA (DE) | 2010-12-15 | — | — | EP | claimed |
| US-7816339-B2 | Treatments for Flaviviridae virus infection | SCHERING CORPORATION (US) | 2010-10-19 | — | — | US | claimed |
| US-20090209483-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | SCHERING CORPORATION | 2009-08-20 | — | — | US | claimed |
| EP-1682109-B1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC AS PEPTIDES IN AMYLOIDOPATHIES | MERZ PHARMA GMBH & CO KGAA (DE) | 2008-10-15 | — | — | EP | claimed |
| CN-101087599-A | 1-aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect | MERZ PHARMA GMBH & CO KGAA (DE) | 2007-12-12 | — | — | CN | claimed |
| EP-1838297-A1 | 1-AMINOCYCLOHEXANE-DERIVATIVES FOR THE TREATMENT OF MULTIPLE SCLEROSIS EMOTIONAL LABILITY AND PSEUDOBULBAR AFFECT | Merz Pharma GmbH & Co. KGaA (DE) | 2007-10-03 | — | — | EP | claimed |
| US-20070082956-A1 | The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity. | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-04-12 | — | — | US | claimed |
| CN-1870984-A | Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic a-beta peptides in amyloidopathies | FOREST LABORATORIES (DE) | 2006-11-29 | — | — | CN | claimed |
| WO-2004037234-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | WO | claimed |
| WO-2004009062-A2 | NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau | IQBAL KHALID (US) | 2004-01-29 | — | — | WO | claimed |
| US-20040019118-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | IQBAL KHALID (US) | 2004-01-29 | — | — | US | claimed |
| US-6602862-B1 | 1-Amino-alkylcyclohexanes as trypanocidal agents | MERZ PHARMA GMBH & CO., KGAA (DE) | 2003-08-05 | — | — | US | claimed |
| EP-1318800-A1 | 1-AMINO-ALKYLCYCLOHEXANES AS TRYPANOCIDAL AGENTS | MERZ + CO. GmbH & Co. (DE) | 2003-06-18 | — | — | EP | claimed |
| EP-1009732-B1 | 1-AMINO-ALKYLCYCLOHEXANE NMDA RECEPTOR ANTAGONISTS | MERZ & CO GMBH & CO (DE) | 2003-05-21 | — | — | EP | claimed |
| WO-2002024186-A1 | 1-AMINO-ALKYLCYCLOHEXANES AS TRYPANOCIDAL AGENTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2002-03-28 | — | — | WO | claimed |
| EP-1009732-A2 | 1-AMINO-ALKYLCYCLOHEXANE NMDA RECEPTOR ANTAGONISTS | MERZ + CO. GmbH & Co. (DE) | 2000-06-21 | — | — | EP | claimed |
| US-6034134-A | 1-Amino-alkylcyclohexane NMDA receptor antagonists | MERZ + CO. GMBH & CO. (DE) | 2000-03-07 | — | — | US | claimed |
| WO-1999001416-A2 | 1-AMINO-ALKYLCYCLOHEXANE NMDA RECEPTOR ANTAGONISTS | MERZ + CO. GMBH & CO. (DE) | 1999-01-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033422-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | HAVCR2, EIF2AK2, HNRNPC | GRIN2D 4839/4885GRIN3B 4076/4885GRIN1 4268/4885 |
| US-20090209483-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | HAVCR2, EIF2AK2, HNRNPC | GRIN2D 4839/4885GRIN3B 4076/4885GRIN1 4268/4885 |
| US-20070082956-A1 | The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity. | GRIN1, OPRL1, GRIN3A | GRIN2D 19/4885GRIN3B 9/4885GRIN1 1/4885 |
| US-20040019118-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | GRIN2A, GRIN1, MAPT | GRIN2D 14/4885GRIN3B 12/4885GRIN1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.